<script>
    // Helper function to check if a value is not a number or null/empty
    function isNaNOrNull(value) {
        if (value === "" || value === null || typeof value === 'undefined') return true;
        const num = parseInt(value);
        return isNaN(num);
    }

    // --- GDMT Data (Therapies and Rules) ---
    // (Keep the gdmtOptions array exactly as it was in the previous version)
    const gdmtOptions = [
         // --- Foundational Pillars ---
            {
                name: "ARNI (Sacubitril/Valsartan)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Preferred first-line over ACEi/ARB for HFrEF NYHA II-IV. Can be started de novo or switched from ACEi/ARB (requires 36hr washout).",
                contraindications: "History of angioedema (ABSOLUTE C/I if prior angioedema to ACEi/ARNI/ARB), concurrent ACEi use, pregnancy. Caution: severe renal impairment, hypotension.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
            {
                name: "ACE Inhibitor (ACEi)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Alternative if ARNI not tolerated or feasible. HFrEF NYHA II-IV.",
                contraindications: "History of angioedema, bilateral renal artery stenosis, pregnancy, hyperkalemia. Caution: renal impairment, hypotension. Preferred over ARNI in breastfeeding.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
            {
                name: "Angiotensin Receptor Blocker (ARB)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Alternative if intolerant to ACEi (e.g., cough) and ARNI not feasible. HFrEF NYHA II-IV.",
                contraindications: "Pregnancy, bilateral renal artery stenosis, hyperkalemia. Caution: renal impairment, hypotension. Prior angioedema to ACEi/ARB is generally a contraindication for ARNI as well.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
             {
                name: "Consider ARB if ACEi Angioedema", // Special case if ACEi angioedema but ARB naive
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && inputs.hasAngioedemaHx,
                indications: "If angioedema occurred ONLY with an ACEi, an ARB *might* be cautiously considered under specialist supervision, but ARNI remains contraindicated. Discuss risks thoroughly.",
                contraindications: "Prior angioedema to ARB or idiopathic angioedema. Pregnancy, bilateral RAS, hyperkalemia.",
                reasoning: (inputs) => "<span class='indication'>Potentially consider ARB (not ARNI) only if angioedema was specific to ACEi and benefits outweigh risks.</span>"
             },
            {
                name: "Beta-Blocker (Evidence-based: Metoprolol Succinate, Carvedilol, Bisoprolol)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40,
                indications: "All patients with HFrEF (LVEF ≤40%), regardless of NYHA class (start once stable/euvolemic). Shown to improve survival.",
                contraindications: "Acute decompensated HF (initiate cautiously once stable), severe bradycardia (<50 bpm), high-degree AV block (without pacemaker), severe asthma/reactive airway disease (use cardioselective like Bisoprolol/Metoprolol cautiously). Titrate slowly."
            },
            {
                name: "Mineralocorticoid Receptor Antagonist (MRA - Spironolactone, Eplerenone)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 35 && inputs.nyha >= 2,
                indications: "HFrEF NYHA II-IV with LVEF ≤35%. Also post-MI with LVEF ≤40% and HF symptoms or diabetes. Monitor K+ and renal function (eGFR) closely.",
                contraindications: "Hyperkalemia (K+ > 5.0 mEq/L at baseline), severe renal impairment (e.g., eGFR < 30 mL/min/1.73m² - check specific drug), anuria, Addison's disease. Eplerenone is more selective (less gynecomastia)."
            },
            {
                name: "SGLT2 Inhibitor (-gliflozin, e.g., Dapagliflozin, Empagliflozin)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40, // Broad HFrEF benefit
                indications: "HFrEF (LVEF ≤40%) across NYHA classes (II-IV often studied) regardless of diabetes status. Reduces HF hospitalizations and CV death. Renal protection benefits.",
                contraindications: "Type 1 Diabetes, history of DKA, severe renal impairment (check specific eGFR cutoffs for initiation/continuation). Risk of genital mycotic infections, volume depletion. Monitor for DKA (can be euglycemic)."
            },
            // --- Symptom Management ---
            {
                name: "Diuretics (Loop: Furosemide, Bumetanide, Torsemide)",
                category: "Symptom Management",
                indicationRule: (inputs) => inputs.nyha >= 2, // Driven by symptoms of congestion
                indications: "Management of fluid retention (congestion) in symptomatic HF (NYHA II-IV). Dose adjusted based on symptoms and volume status. IV for acute decompensation.",
                contraindications: "Anuria. Caution: electrolyte imbalances (hypokalemia, hypomagnesemia), hypotension, severe renal impairment. Can cause ototoxicity at high doses/rapid infusion."
            },
             // --- Add-on / Specific Situation Therapies ---
            {
                name: "Ivabradine",
                category: "Add-on",
                // Rule: LVEF<=35, NYHA II-III, Sinus Rhythm, HR>=70 on max BB
                indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 2 && inputs.nyha <= 3) && !isNaNOrNull(inputs.hr) && inputs.hr >= 70 && !inputs.hasAfib,
                indications: "HFrEF (LVEF ≤35%) in **Sinus Rhythm** with resting HR ≥70 bpm despite maximally tolerated beta-blocker dose (or C/I to BB). NYHA II-III. Reduces HF hospitalizations.",
                contraindications: "AFib, Acute decompensated HF, BP <90/50, sick sinus syndrome, SA block, AV block (2nd/3rd degree unless paced), severe hepatic impairment, pacemaker dependence, strong CYP3A4 inhibitors.",
                reasoning: (inputs) => isNaNOrNull(inputs.hr) ? "<span class='contraindication'>(Requires Heart Rate Input)</span>" : (inputs.hasAfib ? "<span class='contraindication'>(Contraindicated in AFib)</span>" : "")
            },
            {
                name: "Hydralazine + Isosorbide Dinitrate (Hy/ISDN)",
                category: "Add-on",
                 // Rule: LVEF<=40, NYHA III-IV, Self-identified Black
                 indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 3 && inputs.isBlack,
                indications: "Recommended add-on therapy for self-identified Black patients with NYHA Class III-IV HFrEF on optimal foundational therapy (ARNI/ACEi/ARB, BB, MRA).",
                contraindications: "Hypersensitivity. Hydralazine: Caution in CAD, lupus-like syndrome. ISDN: Concurrent PDE5 inhibitors, severe anemia, increased ICP. Both: headache, dizziness, hypotension.",
                 reasoning: (inputs) => inputs.isBlack ? "<span class='indication'>Specific indication for self-identified Black patients with NYHA III-IV.</span>" : ""
            },
            {
                name: "Hydralazine + Isosorbide Dinitrate (Hy/ISDN) - Alternative",
                category: "Add-on",
                // Rule: LVEF<=40, NYHA III-IV, Intolerant to ACEi/ARB/ARNI
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 3 && inputs.hasAngioedemaHx, // Use angioedema Hx as proxy for intolerance
                indications: "Can also be considered as an alternative or add-on in patients (regardless of race) with NYHA Class III-IV HFrEF who cannot tolerate ACEi/ARB/ARNI, or remain symptomatic despite other optimal GDMT.",
                contraindications: "Hypersensitivity. Hydralazine: Caution in CAD, lupus-like syndrome. ISDN: Concurrent PDE5 inhibitors, severe anemia, increased ICP. Both: headache, dizziness, hypotension.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='indication'>Consider if intolerant to ACEi/ARB/ARNI.</span>" : ""
            },
             {
                name: "Digoxin",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2, // Consider if still symptomatic or AF rate control
                indications: "May be considered to reduce HF hospitalizations (no mortality benefit) in HFrEF patients who remain symptomatic (NYHA II-IV) despite optimal GDMT. Can also aid rate control in AFib (use cautiously).",
                contraindications: "VFib, high-degree AV block (unless paced). Narrow therapeutic window - monitor levels, K+, Mg++, renal function. Many drug interactions.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>(Also potential option for AF rate control)</span>" : ""
            },
            {
                name: "Iron (IV Ferric Carboxymaltose / Derisomaltose)",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef <= 45 && inputs.nyha >= 2 && inputs.hasIronDeficiency,
                indications: "Symptomatic HFrEF (LVEF ≤45%, some trials up to 50%) and confirmed Iron Deficiency (Ferritin <100 ng/mL, OR Ferritin 100-299 ng/mL with TSAT <20%). Improves symptoms, QOL, reduces HF hospitalizations.",
                contraindications: "Known hypersensitivity, iron overload. Requires lab confirmation. Monitor for hypersensitivity reactions.",
                reasoning: (inputs) => inputs.hasIronDeficiency ? "<span class='indication'>Indicated due to suspected/known Iron Deficiency (confirm with labs).</span>" : ""
            },
            {
                name: "Vericiguat",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef < 45 && inputs.nyha >= 2 && inputs.hasRecentWorsening,
                indications: "Soluble guanylate cyclase stimulator. Consider for patients with symptomatic chronic HFrEF (LVEF <45%) on GDMT who experience a recent worsening HF event (hospitalization or need for outpatient IV diuretics).",
                contraindications: "Concurrent use of other sGC stimulators or PDE5 inhibitors. Pregnancy. Caution with hypotension.",
                reasoning: (inputs) => inputs.hasRecentWorsening ? "<span class='indication'>Considered due to recent worsening HF event.</span>" : ""
             },
             {
                name: "Anticoagulation",
                category: "Add-on",
                indicationRule: (inputs) => inputs.hasAfib,
                indications: "Indicated for stroke prevention in patients with Atrial Fibrillation (AF) based on CHA₂DS₂-VASc score. Choice between DOAC or warfarin.",
                contraindications: "Active major bleeding, severe thrombocytopenia, high bleeding risk outweighing stroke risk.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>Indicated for stroke prevention due to AF (assess CHA₂DS₂-VASc).</span>" : ""
            },
             // --- Devices ---
             {
                name: "Implantable Cardioverter-Defibrillator (ICD) - Secondary Prevention",
                category: "Device",
                indicationRule: (inputs) => inputs.hasSecondaryIcdIndication,
                indications: "Strongly indicated for survivors of cardiac arrest due to VT/VF, or those with spontaneous sustained VT not due to reversible causes.",
                contraindications: "Terminal illness (<1 year survival), incessant VT/VF, significant psychiatric illness. Procedure risks.",
                reasoning: (inputs) => inputs.hasSecondaryIcdIndication ? "<span class='indication'>Strong indication due to history of life-threatening arrhythmia.</span>" : ""
            },
            {
                name: "Implantable Cardioverter-Defibrillator (ICD) - Primary Prevention",
                category: "Device",
                 // Rule: LVEF<=35, NYHA II-III (or NYHA I LVEF<=30), on GDMT >3mo (NICM) or >40d (post-MI), expected survival >1yr
                 indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 1 && inputs.nyha <= 3) && !inputs.hasSecondaryIcdIndication && ( (inputs.nyha >=2 && inputs.lvef <= 35) || (inputs.nyha == 1 && inputs.lvef <= 30) ),
                indications: "Consider for Primary Prevention if LVEF ≤35% (NYHA II-III) or LVEF ≤30% (NYHA I) due to prior MI (≥40 days post) or non-ischemic CM (≥3 months on optimal GDMT). Must have reasonable expectation of meaningful survival >1 year.",
                contraindications: "Terminal illness (<1 year survival), recent MI (<40d) or revascularization (<3mo), incessant VT/VF, significant psychiatric illness. Procedure risks.",
                 reasoning: (inputs) => (!inputs.hasSecondaryIcdIndication && inputs.lvef <= 35) ? "<span class='indication'>Consider for primary prevention based on LVEF/NYHA class.</span>" : ""
            },
            {
                name: "Cardiac Resynchronization Therapy (CRT / CRT-D)",
                category: "Device",
                // Rule: LVEF<=35, NYHA II-IV ambulatory, Sinus Rhythm, QRS >= 130ms (Ideally LBBB >= 150ms)
                indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 2 && inputs.nyha <= 4) && !isNaNOrNull(inputs.qrs) && inputs.qrs >= 130 && !inputs.hasAfib,
                indications: "LVEF ≤35%, Sinus Rhythm, NYHA Class II, III, or ambulatory IV, on optimal GDMT. Strongest indication with LBBB morphology (check box) and QRS ≥150 ms. Consider for LBBB QRS 130-149 ms, or non-LBBB QRS ≥150 ms (less benefit). Improves symptoms, function, survival (CRT-D includes ICD).",
                contraindications: "AFib (relative - can be done but benefit less clear/needs rate control), life expectancy <1 year. Anatomic limitations. Patient preference.",
                reasoning: (inputs) => isNaNOrNull(inputs.qrs) ? "<span class='contraindication'>(Requires QRS Duration Input)</span>" : (inputs.hasAfib ? "<span class='contraindication'>(Benefit less established/more complex in AFib)</span>" : (inputs.qrs >= 150 && inputs.isLbbb ? "<span class='indication'>(Strongest indication: LBBB & QRS≥150ms)</span>" : (inputs.qrs >= 130 && inputs.isLbbb ? "<span class='indication'>(Indicated: LBBB & QRS 130-149ms)</span>" : (inputs.qrs >= 150 ? "<span class='indication'>(Considered: Non-LBBB & QRS≥150ms)</span>" : ""))))
            },
            // --- Advanced Therapies / Referrals ---
            {
                name: "Mitral Transcatheter Edge-to-Edge Repair (TEER)",
                category: "Advanced",
                // Rule: LVEF 20-50%, NYHA II-IV, Significant Func MR, on GDMT
                indicationRule: (inputs) => inputs.lvef >= 20 && inputs.lvef <= 50 && inputs.nyha >= 2 && inputs.hasFuncMR,
                indications: "Selected patients with chronic moderate-to-severe or severe secondary (functional) Mitral Regurgitation (MR) who remain symptomatic (NYHA II-IV) despite optimal GDMT, and have suitable valve anatomy + favorable LV size. Requires heart team evaluation.",
                contraindications: "Unsuitable anatomy, prohibitive LV dilation/dysfunction, life expectancy <1 year, primary MR.",
                reasoning: (inputs) => inputs.hasFuncMR ? "<span class='indication'>Consider referral for TEER evaluation due to functional MR.</span>" : ""
            },
            {
                name: "Pulmonary Vein Isolation (PVI) Referral",
                category: "Advanced",
                indicationRule: (inputs) => inputs.hasAfib && inputs.lvef <= 40, // AF + HFrEF
                indications: "Catheter ablation (PVI) may be considered for selected HFrEF patients with symptomatic AFib to improve symptoms and potentially reduce HF hospitalizations/mortality, especially if refractory to rate/rhythm control drugs.",
                contraindications: "Prohibitive procedural risk, very enlarged LA, patient preference.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>Consider referral for PVI evaluation due to AFib in HFrEF.</span>" : ""
            },
            {
                name: "LVAD / Heart Transplant Referral",
                category: "Advanced",
                // Rule: Advanced HF (NYHA III-IV refractory), LVEF<=35
                indicationRule: (inputs) => inputs.lvef <= 35 && inputs.nyha >= 3 && (inputs.hasRecentWorsening || inputs.nyha == 4), // Proxy for advanced/refractory
                indications: "Patients with advanced, refractory HFrEF (Stage D) despite optimal medical/device therapy (e.g., NYHA III-IV symptoms, recurrent hospitalizations, end-organ dysfunction due to low output). Needs evaluation at specialized center.",
                contraindications: "Irreversible end-organ damage (renal, hepatic), severe irreversible PHTN, active malignancy, prohibitive comorbidities, psychosocial issues, non-adherence."
            },
            // --- General & Avoid ---
            {
                name: "Multi-Professional Disease Management",
                category: "General",
                indicationRule: (inputs) => inputs.nyha >= 2, // Especially important for symptomatic patients
                indications: "Essential for all HF patients, particularly those with higher symptom burden (NYHA II-IV) or recent hospitalizations. Includes patient education, self-care support, medication optimization, coordination of care, addressing psychosocial factors. Improves QOL and reduces readmissions.",
                contraindications: "N/A",
                reasoning: (inputs) => inputs.nyha >= 3 ? "<span class='indication'>(Particularly crucial for NYHA III/IV)</span>" : ""
            },
            {
                name: "Lifestyle & General Measures",
                category: "General",
                indicationRule: () => true,
                indications: "Sodium restriction (~<2-3g/day), fluid restriction (~1.5-2L/day if congested/hyponatremic), regular exercise/cardiac rehab, weight management, smoking cessation, influenza/pneumococcal vaccination, manage comorbidities (HTN, DM, Afib, Sleep Apnea).",
                contraindications: "N/A"
            },
            {
                name: "Medications to AVOID",
                category: "Avoid",
                indicationRule: () => true,
                indications: "NSAIDs (inc. COX-2 inhibitors), TZDs (pioglitazone), Non-dihydropyridine CCBs (Verapamil, Diltiazem in HFrEF), Cilostazol, Class I antiarrhythmics, Dronedarone.",
                contraindications: "N/A"
            }
    ];


    // --- Function to generate the initial summary sentence ---
    function generateSummarySentence(inputs) {
        let sentence = "";
        const isHFrEF = inputs.lvef <= 40;
        const isHFpEF = inputs.lvef >= 50;
        const medicationsToAvoid = "NSAIDs, TZDs, Non-DHP CCBs (in HFrEF)"; // Basic list

        if (isHFpEF && !inputs.hasSecondaryIcdIndication) {
            // HFpEF Summary
            sentence = `<strong>Summary:</strong> For HFpEF (LVEF ≥ 50%), prioritize managing congestion (<strong>Diuretics</strong> prn), treating underlying causes, and initiating an <strong>SGLT2 Inhibitor</strong>. Consider MRAs based on phenotype. Avoid HFrEF-specific GDMT without other indications. Key medications to avoid include ${medicationsToAvoid}. See details below.`;
        } else if (isHFrEF) {
            // HFrEF Summary
            let foundational = [];
            // RAAS Inhibitor
            if (inputs.nyha >= 2) {
                if (inputs.hasAngioedemaHx) {
                    foundational.push("Consider ARB cautiously if only ACEi angioedema");
                } else {
                    foundational.push("ARNI (preferred) or ACEi/ARB");
                }
            } else {
                 foundational.push("ARNI/ACEi/ARB (if NYHA II-IV)"); // Note class requirement
            }
            // Beta-Blocker
            foundational.push("Beta-Blocker");
             // MRA
            if (inputs.lvef <= 35 && inputs.nyha >= 2) {
                 foundational.push("MRA");
            } else {
                 foundational.push("MRA (if LVEF ≤ 35% & NYHA II-IV)"); // Note requirements
            }
            // SGLT2i
            foundational.push("SGLT2 Inhibitor");

            let foundationalText = foundational.filter(f => !f.includes("(")).join(", "); // Basic list
            let conditionalText = foundational.filter(f => f.includes("(")).join("; "); // More specific criteria list


            sentence = `<strong>Summary:</strong> For HFrEF (LVEF ≤ 40%), prioritize initiating/titrating foundational GDMT: <strong>${foundationalText}</strong>. ${conditionalText ? `Ensure criteria met for: ${conditionalText}. ` : ''}Always avoid: <strong>${medicationsToAvoid}</strong>. `;

             // Add notes based on checkboxes if applicable
             if (inputs.hasAfib) sentence += "Anticoagulation indicated for AFib. ";
             if (inputs.hasAngioedemaHx) sentence += "ARNI/ACEi contraindicated. ";
             if (inputs.hasAfib && !isNaNOrNull(inputs.hr) && inputs.hr >= 70 && inputs.lvef <= 35) sentence += "Ivabradine likely not indicated (AFib). ";
             if (inputs.hasIronDeficiency) sentence += "Consider IV Iron. ";

             sentence += "Review specific indications for add-on therapies and devices below.";

        } else {
             // HFmrEF or unclear LVEF
             sentence = `<strong>Summary:</strong> For LVEF between 41-49% (HFmrEF), management often mirrors HFrEF but evidence varies. Consider <strong>SGLT2 Inhibitors</strong> and manage symptoms/comorbidities. Always avoid: <strong>${medicationsToAvoid}</strong>. Review specific therapy details below.`;
        }

        return `<p style="font-weight: bold; background-color: #eef; padding: 10px; border-radius: 4px;">${sentence}</p>`;
    }


    // --- Form Submission Logic ---
    document.getElementById('gdmtForm').addEventListener('submit', function(event) {
        event.preventDefault(); // Prevent page reload

        // Collect core inputs
        const inputs = {
            age: parseInt(document.getElementById('age').value),
            lvef: parseInt(document.getElementById('lvef').value),
            nyha: parseInt(document.getElementById('nyha').value),
            hr: parseInt(document.getElementById('hr').value), // Will be NaN if empty
            qrs: parseInt(document.getElementById('qrs').value), // Will be NaN if empty
            // Collect checkbox inputs
            hasAfib: document.getElementById('hasAfib').checked,
            hasIronDeficiency: document.getElementById('hasIronDeficiency').checked,
            hasFuncMR: document.getElementById('hasFuncMR').checked,
            isBlack: document.getElementById('isBlack').checked,
            hasAngioedemaHx: document.getElementById('hasAngioedemaHx').checked,
            hasSecondaryIcdIndication: document.getElementById('hasSecondaryIcdIndication').checked,
            hasRecentWorsening: document.getElementById('hasRecentWorsening').checked,
            isLbbb: document.getElementById('isLbbb').checked
        };

        const resultsDiv = document.getElementById('results');
        resultsDiv.innerHTML = ''; // Clear previous results completely

        // Generate and add the summary sentence FIRST
        resultsDiv.innerHTML += generateSummarySentence(inputs);

        // Basic HFpEF check (for filtering subsequent results)
        if (inputs.lvef >= 50 && !inputs.hasSecondaryIcdIndication) {
            // Display filtered results for HFpEF
            displayResults(inputs, resultsDiv, gdmtOptions.filter(opt =>
                 ['General', 'Avoid', 'Symptom Management'].includes(opt.category) ||
                 opt.name.includes('SGLT2') ||
                 opt.name.includes('MRA') || // MRA might be considered in specific HFpEF phenotypes
                 (opt.name.includes('Anticoagulation') && inputs.hasAfib) // Anticoag if AFib present
             ));
        } else {
            // Display full results for HFrEF/HFmrEF
             displayResults(inputs, resultsDiv, gdmtOptions);
        }
    });

    // Function to display results (Mostly unchanged from previous version)
    function displayResults(inputs, resultsDiv, optionsToDisplay) {
         // Group results by category
        const categories = {
            "Foundational": [],
            "Symptom Management": [],
            "Add-on": [],
            "Device": [],
            "Advanced": [],
            "General": [],
            "Avoid": []
        };

         // Use a Set to avoid duplicate entries
         const addedTherapies = new Set();

        optionsToDisplay.forEach(option => {
             if ((option.indicationRule(inputs) || ['General', 'Avoid'].includes(option.category)) && !addedTherapies.has(option.name)) {

                let contraNotes = "";
                if (option.category === 'Foundational' && inputs.hasAngioedemaHx && (option.name.includes('ARNI') || option.name.includes('ACEi'))) {
                     // Skip adding standard ARNI/ACEi if angioedema Hx - handled by specific rule/summary now
                     return;
                }
                 if (option.name.includes('Ivabradine') && inputs.hasAfib) {
                    contraNotes = "<span class='contraindication' style='display:block; margin-top:3px;'>Note: Generally contraindicated in AFib.</span> ";
                     // Don't return; let it display with the note if rule otherwise matches
                 }
                 if (option.name.includes('CRT') && inputs.hasAfib) {
                     contraNotes = "<span class='contraindication' style='display:block; margin-top:3px;'>Note: Benefit less established/more complex in AFib.</span> ";
                 }


                let reasoningText = option.reasoning ? option.reasoning(inputs) : "";
                let displayItem = `
                    <div class="result-item">
                        <h3>${option.name}</h3>
                        ${reasoningText ? `<span class="reason">${reasoningText}</span>` : ''}
                         ${contraNotes ? `<span class="reason">${contraNotes}</span>` : ''}
                         <p><strong class="indication">Indications:</strong> ${option.indications}</p>
                        <p><strong class="contraindication">Contraindications/Cautions:</strong> ${option.contraindications}</p>
                    </div>
                `;

                // Special handling for Avoid category
                 if (option.category === 'Avoid') {
                     displayItem = `
                         <div class="result-item">
                            <h3>${option.name}</h3>
                            <p><strong class="contraindication">Details:</strong> ${option.indications}</p>
                         </div>
                     `;
                 }
                 // Special handling for General category
                 else if (option.category === 'General') {
                      displayItem = `
                         <div class="result-item">
                             <h3>${option.name}</h3>
                              ${reasoningText ? `<span class="reason">${reasoningText}</span>` : ''}
                             <p><strong class="indication">Details:</strong> ${option.indications}</p>
                         </div>
                     `;
                 }

                // Filter out foundational therapies not matching criteria even if rule technically passes (e.g. MRA if LVEF > 35)
                 if (option.category === 'Foundational') {
                    let clearlyIndicated = false;
                    if(option.name.includes('Beta-Blocker') && inputs.lvef <= 40) clearlyIndicated = true;
                    if(option.name.includes('SGLT2') && inputs.lvef <= 40) clearlyIndicated = true;
                    if((option.name.includes('ARNI') || option.name.includes('ACEi') || option.name.includes('ARB')) && inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx) clearlyIndicated = true;
                    if(option.name.includes('Consider ARB if ACEi Angioedema') && inputs.lvef <= 40 && inputs.nyha >= 2 && inputs.hasAngioedemaHx) clearlyIndicated = true;
                    if(option.name.includes('MRA') && inputs.lvef <= 35 && inputs.nyha >= 2) clearlyIndicated = true;

                    if(!clearlyIndicated && !(option.name.includes('Consider ARB'))) return; // Skip if foundational criteria not met clearly
                 }


                categories[option.category].push(displayItem);
                addedTherapies.add(option.name); // Mark as added
             }
        });

        // Display grouped results
        let sectionAdded = false; // Track if any sections are added after the summary
        for (const category in categories) {
            if (categories[category].length > 0) {
                // Only add the H2 if it wasn't added before (for this category)
                 if (!document.getElementById(`category-header-${category}`)) {
                     resultsDiv.innerHTML += `<h2 id="category-header-${category}">${category.replace(/([A-Z])/g, ' $1').trim()} Therapies</h2>`;
                 }
                 resultsDiv.innerHTML += categories[category].join('');
                 sectionAdded = true;
            }
        }

        // Handle case where only summary + avoid/general categories show up
         if (!sectionAdded && (categories['General'].length > 0 || categories['Avoid'].length > 0) ) {
            // Already displayed general/avoid, maybe add a note?
             // resultsDiv.innerHTML += '<p>No specific additional therapies matched the criteria beyond foundational principles and medications to avoid.</p>';
         } else if (!sectionAdded && categories['General'].length === 0 && categories['Avoid'].length === 0) {
            // Truly nothing matched beyond summary
             resultsDiv.innerHTML += '<p>No specific therapies strongly matched the selected criteria based on these simplified rules beyond the initial summary. Review guidelines.</p>';
         }
    }
</script>
